Status: Not yet recruiting
A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
Evaluation of the efficacy and safety of Trilaciclib in preventing myelosuppression caused by topoisomerase I inhibitor type ADC drugs
Participants needed: 96
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Tianjin Medical University Cancer Institute and HospitalUpdated: Jul 30, 2026Locations: 2
Eligibility criteria
The patient voluntarily participated in this study, signed the informed consent... [+10]
1. No history of myeloid leukemia, myelodysplastic syndrome or concurrent sickle...